By Daniel Kavanagh (WCG)2024-01-15T14:23:08
Dr Daniel Kavanagh, Senior Scientific Advisor, Gene Therapies, Vaccines and Biologics at WCG, discusses how monoclonal antibodies are limited by their ability to only recognise tumour antigens expressed on the outside surface of a cell. In this article he explains how investigational genetically engineered medicinal products are leveraging T-cell receptors ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-11-16T07:00:00Z
Author Dr Martin Baraibar
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-11-18T07:00:00
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-09-23T15:00:00
Sponsored by BioIVT
2023-05-10T11:18:16
Sponsored by Revvity
2026-07-08T07:58:00
Contributor Dr Nick Lynch, By Dr Raminderpal Singh
Site powered by Webvision Cloud